Effect of anticoagulant and platelet inhibition on the risk of bacteremia among patients with acute pyelonephritis: a retrospective cohort study

Svava E. Steiner1,2, Gustaf Edgren3,4, Keira Melican1,2, Agneta Richter-Dahlfors1,2 and Annelie Brauner5,6*

Abstract

Background: An increasing number of patients are being prescribed anticoagulants and platelet inhibitors (antithrombotic treatment). Basic research has suggested an association between antithrombotic treatment and bacteremia during kidney infection. Here, we investigated the association between antithrombotic treatment, bacteremia and acute kidney injury in patients with acute pyelonephritis.

Methods: A retrospective cohort study was conducted in a large university hospital in Sweden. Data were retrieved from electronic medical records for adult patients with acute pyelonephritis in 2016. The main outcome was bacteremia and secondary outcome acute kidney injury. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated through multiple logistic regression. Treatment with different groups of antithrombotic agents were compared to no antithrombotic treatment.

Results: 1814 patients with acute pyelonephritis were included, in whom bacteremia developed in 336 (18.5%). Low-molecular-weight heparin (LMWH) at prophylactic doses was associated with a lower risk of bacteremia, compared to no antithrombotic treatment (OR 0.5; 95% CI 0.3–0.7). Other antithrombotic treatments were not associated with a risk of bacteremia. Additionally, patients with prophylactic doses of LMWH had a lower risk of acute kidney injury (OR 0.5; 95% CI 0.3–0.8).

Conclusions: We found no association between antithrombotic treatment and an increased risk of bacteremia during acute pyelonephritis. Conversely, patients with prophylactic doses of LMWH had a slightly reduced risk of bacteremia. LMWH at prophylactic doses was also associated with a lower risk of acute kidney injury. Our results suggest that it is safe to continue antithrombotic treatment during acute pyelonephritis, in regards to bacteremia and acute kidney injury risk.

Keywords: Acute kidney injury, Anticoagulants, Bacteremia, Platelet aggregation inhibitors, Urinary tract infection

Background

Acute pyelonephritis is a common bacterial infection, often caused by Gram-negative bacteria, predominantly Escherichia coli. The infection can sometimes be associated with complications such as bacteremia and urosepsis [1], as well as acute kidney injury [2]. Considering the relatively high frequency of bacteremia, combined with...
high reported mortality rates [3], it is important to identify potential risk factors for severe outcomes.

During bacterial infection, there is an interplay between inflammation and coagulation, with thrombosis playing an important role in innate immunity [4–6]. Many studies have investigated anticoagulants as potential adjunctive treatments of sepsis [7–12]. Little is known, however, about the role of coagulation during localized bacterial infections, prior to systemic spread of bacteria. In rodents, vascular thrombus formation has been observed during experimental kidney infection [13–17]. We previously visualized clot formation in peritubular capillaries following a localized kidney tubule infection [14–16]. This clot formation appeared to be protective against urosepsis, as anticoagulant treatment delayed the initiation of clotting and resulted in systemic spread of bacteria [14]. While these results suggested a role of blood clots in preventing bacteremia in rodents, it implied that patients with antithrombotic treatment may be at higher risk of developing urosepsis during acute pyelonephritis.

The number of patients being prescribed different types of antithrombotic drugs (both anticoagulants and platelet inhibitors) is increasing worldwide. This is partially due to the introduction of routine screenings for atrial fibrillations along with an aging population [18]. Considering both the relatively high incidence of acute pyelonephritis, and the high numbers of patients on antithrombotic treatment, it is important to evaluate the possible impact of such treatment on the risk of developing bacteremia for patients with urinary tract infections. In this study, we investigated if antithrombotic treatment is associated with an increased risk of bacteremia in patients with acute pyelonephritis. While coagulation surrounding infected areas might potentially prevent bacteremia, it may also result in increased renal injury, which is important to investigate from a clinical perspective. Therefore, we also studied the association between antithrombotic treatment and risk of acute kidney injury among patients with acute pyelonephritis.

**Methods**

**Study design and setting**

The overall aim of the study was to investigate if antithrombotic treatment is associated with an increased risk of bacteremia or acute kidney injury in patients with acute pyelonephritis. We conducted a retrospective cohort study using data from the electronic medical record system at Karolinska University Hospital in Stockholm, Sweden. The study was based on all inpatients diagnosed with acute pyelonephritis, from January 1 to December 31, 2016.

**Data sources and participants**

We extracted data from two sources. Data on all bacterial cultures were extracted from the laboratory information management system kept by Karolinska University Laboratory, where all microbiological analyses for the hospital are performed. Using unique national registration numbers, assigned to all inhabitants of Sweden, data were linked to the hospital electronic medical record system. This provided data on demographics (age and sex), antithrombotic use (see Additional file 1: Table S1), vital signs (heart rate, body temperature, blood pressures, peripheral oxygen saturation, respiratory rate, and Glasgow Coma Scale [GCS]), objective physical findings (body mass index [BMI]), laboratory findings, information regarding the hospital visit (ward, duration of hospital stay, reason for hospitalization), and comorbidities.

From the linked hospital record data, we identified all adult patients with suspected acute pyelonephritis (defined as growth of bacteria in urine combined with body temperature ≥ 38 °C or a diagnosis of pyelonephritis, as defined in Additional file 1: Table S2). If a patient had more than one episode of acute pyelonephritis during the study period, only the first episode was included. Urine samples with growth of bacteria considered as normal microbiota or contamination were excluded. To allow the ascertainment of the occurrence of bacteremia, the study population was further restricted to patients with at least 1 blood culture drawn within one day of the urine culture. See Fig. 1 for study profile. For our secondary analysis, investigating the risk of acute kidney injury, we included all patients with acute pyelonephritis, and with available data on the outcome measurement.

![Flowchart](image_url)
Conditions were identified and classified using ICD-10. Antithrombotic treatment, only one treatment was chosen for study profile of this sub-cohort.

Definitions

Antithrombotic treatment was defined as having a recorded continuous use of drugs with Anatomic Therapeutic Chemical (ATC) classification codes starting with “B01” from at least one day prior to the acute pyelonephritis episode and at least until the day of the positive urine culture (see Additional file 1: Table S1 for all included antithrombotic treatments). Patients without recorded continuous use of antithrombitics during the study period were considered unexposed. For our main analyses, we stratified antithrombotic treatment into five categories. If a patient was prescribed more than one antithrombotic treatment, only one treatment was chosen for each patient in the following order: (i) low-molecular-weight heparin (LMWH) at therapeutic doses, (ii) low-molecular-weight heparin (LMWH) at prophylactic doses, (iii) other anticoagulants (including Warfarin and direct oral anticoagulants [DOACs]), (iv) platelet-inhibitors except acetylsalicylic acid, and (v) acetylsalicylic acid (for details, see Additional file 1: Table S2). Comorbid conditions were identified and classified using ICD-10 coding. The definitions used for comorbidities of interest or characteristics important for cohort definition are listed in Additional file 1: Table S2.

Outcomes

The main outcome was bacteremia, defined as at least one positive blood culture drawn within one day of the urine culture, with growth of the same bacterial strain in blood and urine. If a blood culture did not show any growth of bacteria or was discordant to the urine culture, it was considered negative. In secondary analyses, we used acute kidney injury as outcome. This was defined as either a discharge diagnosis of acute kidney injury, or as an increase of serum creatinine by ≥ 26.4 µmol/L, or a relative increase of serum creatinine of ≥ 50% within 48 h from baseline at the time of the urine culture, according to Acute Kidney Injury Network classification stage 1 or higher [19]. Baseline serum creatinine levels were defined as the latest value taken more than one day before the acute pyelonephritis episode.

Statistical analysis

Descriptive statistics were reported as absolute numbers and percentage for categorical variables, and median with interquartile range for age. Odds ratios (OR) of bacteremia, and acute kidney injury, comparing antithrombotic treatment to no antithrombotic treatment at the time of the acute pyelonephritis episode, were calculated using multiple logistic regression. Adjusted ORs, with 95% confidence intervals (CIs) were reported. In addition to terms for antithrombotic treatment, the logistic regression models included terms for age, sex, BMI, and the following comorbidities: malignancy, diabetes, hypertension, chronic renal failure, chronic heart failure, chronic liver disease, cardiovascular disease, thromboembolism and coagulopathy. Variables were chosen a priori based on clinical judgment. Age and BMI were included as categorical variables (see Additional file 1: Table S2), while all other variables were treated as binary categorical predictors. For BMI, missing data was included as a separate category. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

Results

Study population and characteristics

In total 4387 patients with positive urine cultures were considered for inclusion (Fig. 1). Of these 2125 were found to have acute pyelonephritis. Blood cultures were taken from 2053 of these patients. 1814 patients with acute pyelonephritis remained in the final cohort after exclusion of cases where urine culture revealed growth of microorganisms interpreted as clinically not significant or with inconclusive results. In this cohort, 672 (37.0%) were on some form of anticoagulant or platelet inhibitor (antithrombotic) treatment at the time of the urine culture.

Patients with antithrombotic treatment were more often male, older, had a higher BMI, and were more likely to have a history of diabetes, malignancy, hypertension, chronic renal failure, congestive heart failure, tachycardia arrhythmia (including atrial fibrillation), cardiovascular disease and thromboembolism (Table 1). In the full cohort, the most common bacterial strain found in urine was E. coli (n=1078), followed by Enterococcus species (n=281), and Klebsiella pneumoniae (n=192) (Additional file 1: Table S3). However, E. coli infection was less common among patients with antithrombotic treatment, who more often had polymicrobial infections. While an indwelling urinary catheter was more common among patients with antithrombotic treatment, we found no differences in levels of C-reactive protein (CRP) or white blood cell (WBC) count between patients with or without antithrombotic treatment (Table 1). Among the 1814 patients with acute pyelonephritis, 336 (18.5%) had bacteremia, and E. coli was the most common species found in blood cultures (n=221), followed by Klebsiella pneumoniae (n=41) (Additional file 1: Table S4). Anticoagulants were prescribed to 396, and platelet inhibitors in 328 of the patients with acute pyelonephritis. LMWH was prescribed at therapeutic doses to 95 patients, and at prophylactic doses to 214 patients. Non-LMWH anticoagulants (including Warfarin and DOAC) were
| Clinical characteristics of patients in our cohort | Cohort | Antithrombotic treatment |
|-------------------------------------------------|--------|------------------------|
| | n = 1814 (100%) | Yes n = 672 (37.0%) | No n = 1142 (63.0%) |
| Female, n (%) | 959 (52.9) | 284 (42.3) | 675 (59.1) |
| Age, yrs, n (%) | | | |
| < 20 | 13 (0.7) | 3 (0.4) | 10 (0.9) |
| 20–34 | 145 (8.0) | 19 (2.8) | 126 (11.0) |
| 35–49 | 197 (10.9) | 35 (5.2) | 162 (14.2) |
| 50–64 | 383 (21.1) | 120 (17.9) | 263 (23.0) |
| ≥ 65 | 1076 (59.3) | 495 (73.6) | 581 (50.9) |
| Age, median yrs (IQR) | 68 (55–79) | 73 (64–81) | 65 (49–76) |

| Anticoagulant or platelet inhibitor, n (%)* | | |
|-------------------------------------------------|--------|------------------------|
| Any anticoagulant | 396 (21.8) | 396 (58.9) | – |
| LMWH therapeutic | 95 (5.2) | 95 (14.1) | – |
| LMWH prophylactic | 214 (11.8) | 214 (31.8) | – |
| Non-LMWH anticoagulants | 102 (5.6) | 102 (15.2) | – |
| Any platelet inhibitor | 328 (18.1) | 328 (48.8) | – |
| Non-ASA platelet inhibitor | 68 (3.7) | 68 (10.1) | – |
| ASA | 304 (16.8) | 304 (45.2) | – |

| Pathogen in urine, n (%)* | | |
|-------------------------------------------------|--------|------------------------|
| Any Gram-negative | 1579 (86.5) | 567 (84.4) | 1003 (87.8) |
| Any *E. coli* | 1078 (59.4) | 333 (49.6) | 745 (65.2) |
| Any Gram-negative other than *E. coli* | 547 (30.2) | 254 (37.8) | 293 (25.7) |
| Any Gram-positive | 333 (18.4) | 155 (23.1) | 178 (15.6) |
| Any other pathogen than *E. coli* (both gram-negative and gram-positive) | 834 (46.0) | 383 (57.0) | 451 (39.5) |
| ≥ 2 pathogens in urine | 165 (9.1) | 82 (12.2) | 83 (7.3) |

| Clinical presentation, n (%)* | | |
|-------------------------------------------------|--------|------------------------|
| Fever | 1806 (99.6) | 671 (99.9) | 1135 (99.4) |
| Urinary catheter | 368 (20.3) | 211 (31.4) | 157 (13.7) |
| CRP levels, median mg/L (IQR) | 84.5 (38–162) | 84 (40–161) | 85 (36–162) |
| WBC count, median count × 10^9/L (IQR) | 11.6 (8.2–15.5) | 12.0 (8.6–15.7) | 11.4 (7.9–15.4) |

| Comorbidities, n (%)* | | |
|-------------------------------------------------|--------|------------------------|
| Diabetes | 295 (16.3) | 148 (22.0) | 147 (12.9) |
| Malignancy | 583 (32.1) | 231 (34.8) | 352 (30.8) |
| Hypertension | 521 (28.7) | 287 (42.7) | 234 (20.5) |
| Chronic Renal Failure | 165 (9.1) | 96 (14.3) | 69 (6.0) |
| Chronic Liver Disease | 25 (1.4) | 6 (0.9) | 19 (1.7) |
| Congestive Heart Failure | 208 (11.5) | 122 (18.2) | 86 (7.5) |
| Tachycardia arrhythmia | 263 (14.5) | 160 (23.8) | 103 (9.0) |
| Atrial fibrillation | 249 (13.7) | 153 (22.8) | 96 (8.4) |
| Cardiovascular disease | 320 (17.6) | 229 (34.1) | 91 (8.0) |
| Thromboembolism | 128 (7.1) | 83 (12.4) | 45 (3.9) |
| Coagulopathy | 71 (3.9) | 19 (2.8) | 52 (4.6) |
| BMI | | | |
| < 18.5 kg/m² | 241 (13.3) | 96 (14.3) | 145 (12.7) |
| 18.5–25 kg/m² | 405 (22.3) | 156 (23.2) | 249 (21.8) |
| 25–30 kg/m² | 369 (20.3) | 165 (24.6) | 204 (17.9) |
| ≥ 30 kg/m² | 198 (10.9) | 93 (13.8) | 105 (9.2) |
| Missing | 601 (33.1) | 162 (24.1) | 439 (38.4) |

IQR: inter quartile range; LMWH: low molecular weight heparin; ASA: Acetylsalicylic acid; CRP: C-reactive protein; WBC: white blood cell; BMI: Body Mass Index

* Categories are potentially overlapping
prescribed to 87 patients, while acetylsalicylic acid was prescribed to 213 and non-acetylsalicylic acid platelet inhibitors to 63 patients.

**Bacteremia among patients with acute pyelonephritis**

In the first logistic regression analyses, we compared the risk of bacteremia in patients with different types of antithrombotic treatment to patients without such treatment. With the exception of a lower risk of bacteremia among patients treated with LMWH at prophylactic doses (adjusted OR 0.5, 95% CI 0.3–0.7), there were no differences in risk of bacteremia between the other treatments. The other treatments included LMWH at therapeutic doses (adjusted OR 0.7, 95% CI 0.4–1.4), non-LMWH anticoagulants (adjusted OR 1.0, 95% CI 0.6–1.8), non-acetylsalicylic acid platelet inhibitors (adjusted OR 0.9, 95% CI 0.4–1.9), and acetylsalicylic acid (adjusted OR 1.0, 95% CI 0.7–1.6) (Fig. 2).

**Acute kidney injury among patients with acute pyelonephritis**

1419 patients with acute pyelonephritis had sufficient data to allow ascertainment of renal function throughout the acute pyelonephritis episode. Of these, 148 (10.4%) developed acute kidney injury (Fig. 3). When fitted in a logistic regression model, patients treated with LMWH at prophylactic doses had statistically significantly lower risks of acute kidney injury compared to no antithrombotic treatment, with odds ratios of 0.5 (95% CI 0.3–0.8). There were no differences in risk of acute kidney injury between the other treatments and no antithrombotic treatment (Fig. 3).

**Discussion**

In this study we tested a hypothesis that following bacterial infection of renal tubules, coagulation in local capillaries form a physical barrier that limits the systemic spread of bacteria. Antithrombotic drugs may inhibit this apparently protective process and thereby promote bacteremia. This hypothesis was inspired by our experimental studies in rats as well as reports exploring the
initiation of coagulation during localized acute pyelonephritis [14, 17, 20–22]. In addition to hindering systemic bacterial spread, we speculated that this vascular disruption may also lead to more prominent kidney injury due to local ischemia. In contrast to our initial hypothesis, we did not find any convincing evidence of an increased risk of bacteremia in patients on antithrombotic treatment during acute pyelonephritis. Rather, we found a slightly lower risk of both bacteremia and acute kidney injury in patients undergoing treatment with LMWH at prophylactic doses, compared to patients without any antithrombotic treatment. As such, our results suggest that it is safe to continue ongoing antithrombotic treatment during acute pyelonephritis, with regards both to the risk of bacteremia and acute kidney injury.

To our knowledge, this is the first study on the association between antithrombotic treatment and bacteremia in patients with acute pyelonephritis. While there are several studies on anticoagulant therapy as adjunctive treatment of sepsis [7–12], studies investigating associations between anticoagulants or platelet inhibitors and the risk of bacteremia are scarce. A small number of studies have investigated an association between anticoagulant treatment and risk of bacteremia, but did not take the site of infection origin into consideration [23, 24]. A lower risk of bacteremia has been reported among patients with atrial fibrillation treated with dabigatran, compared to patients treated with factor Xa-inhibitor [23]. However, this particular study did not compare risks of bacteremia in patients with and without anticoagulant treatment, which was the focus of our study. In contrast to a study showing increased risk of intravenous catheter-related bacteremia among patients with systemic anticoagulant treatment [24], we found a slightly reduced risk of bacteremia among patients in our cohort with prophylactic doses of LMWH. However, the causative microorganisms and their mode of infection are very different between these two studies, which could explain our contradictory findings.

The anticoagulant used in our original animal studies was unfractioned heparin [14], which is less frequently used in clinical practice and was not prescribed to any patients included in our current study. However, 309 patients were treated with LMWH, among whom we saw a reduced risk of bacteremia. Together with our observation that there was no difference in risk of bacteremia among patients with therapeutic doses of LMWH or other antithrombotics, this suggests that patients with antithrombotic treatment do not have higher risk of bacteremia during acute pyelonephritis. Still, we are cautious to suggest any strong protective effect of LMWH at prophylactic doses.

While it is clinically comforting that we did not find any evidence of increased risk of bacteremia among patients with antithrombotic treatment, we did observe that treatment with prophylactic doses of LMWH reduced the risk of acute kidney injury. This is in line with recent studies showing that both unfractioned heparin and LMWH treatment prevent acute kidney injury during acute pyelonephritis and sepsis [25–28]. While our results partly support our hypothesis that activation of coagulation might contribute to acute kidney injury during acute pyelonephritis, the lack of convincing evidence of a protective effect of LMWH at therapeutic doses or non-LMWH anticoagulants, means we cannot draw any conclusions regarding the underlying mechanisms of these findings. The multifaceted biological effects of heparins, including both anticoagulatory [29] and immunomodulatory effects [30–34], complicate the interpretation of both clinical and experimental studies using heparin or LMWH. However, we believe that our results highlight a potentially important association for further study.

The strengths of our study include a relatively large sample size and our focus on a group of patients who are at a potentially higher risk of bacteremia. We also included and adjusted for a range of clinically relevant covariates and potential confounders, with little or no missing data. Despite the strengths, there are of course limitations to consider. First, it is a single-center, observational study, and therefore generalization of our results should be interpreted cautiously. Being the first study of its kind, however, our work motivates further larger-scale prospective studies to validate these results. Second, there are restrictions in the available data. Due to the retrospective nature of the study, we did not have access to structured data for each hospital stay. For example, we do not know the exact duration of symptoms for each patient, and they were therefore likely included in the study at different stages of infection. Patients with antithrombotic treatment may have different comorbidity burdens, and therefore have a different propensity to seek medical care. Thus, patients with and without antithrombotic treatment might have different baseline risks of bacteremia, as a longer duration of symptoms prior to diagnosis and initiation of antibiotic treatment, is related to higher risk of bacteremia and sepsis [35]. Further, due to the presence of certain comorbidities clinicians may be more inclined to admit patients with antithrombotic treatment to the hospital or to start antibiotic treatment earlier or with intravenous antibiotics. These effects are likely not fully removed by adjustment for comorbidity and other patient factors. Patients on anticoagulants may also have been kept in the hospital long enough to follow up with further serum creatinine measurements, allowing for detection of acute kidney
injury. Therefore, missing data from patients without antithrombotic treatment may have resulted in the introduction of bias. Moreover, we did not have conclusive data on indications for antithrombotic treatment and could therefore not adjust for these as possible confounders. Thirdly, we only include patients treated in a university hospital setting, and only where blood cultures were obtained, which might limit generalizability. However, in this study we deliberately chose to observe a patient group with reported higher risk of bacteremia and where the occurrence of the outcome could be accurately ascertained. Further, our results show that bacteremia was present in approximately 20% of the cases, which is in line with earlier findings [1, 36, 37].

Conclusions
Patients with acute pyelonephritis and antithrombotic treatment do not appear to have a higher risk of developing bacteremia. In contrast to our initial hypothesis, we found a slightly lower risk of bacteremia among patients with LMWH treatment at prophylactic doses. For acute kidney injury, concordant with our hypothesis, we found that treatment with LMWH at prophylactic doses also seem to have protective effects. The observed decreases need to be confirmed in future studies. Collectively, our findings suggest that it is safe to continue antithrombotic treatments in patients with acute pyelonephritis if there are no other contraindications. While our results might indicate that coagulation has a role during acute pyelonephritis, future studies validating the potential protective effects, and investigating possible causative relationships are needed.

Abbreviations
ATC: Anatomic Therapeutic Chemical (ATC) classification codes; ASA: Acetylsalicylic acid; BMI: Body mass index; CI: Confidence interval; DOAC: Direct oral anticoagulants; GCS: Glasgow Coma Scale; IQR: Inter quartile range; LMWH: Low-molecular-weight heparin; OR: Odds ratio.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07474-4.

Additional file 1: Table S1. Antithrombotic drugs included in the analyses. Table S2. Definitions of disease, co-morbidities, and outcomes. Figure S1. Flowchart of the study population and cohort studied in sub-analysis. Table S3. Bacterial strains found in urine cultures of 1814 patients. Table S4. Bacterial strains found in positive blood cultures of 336 patients (18.5%) out of a total of 1814 patients.

Acknowledgements
We would like to thank Catrine Angbjär and Marie-Christine Berglund for helping us with data retrieval.

Author contributions
AR-D, KM, AB and SES conceived the project. SES, GE and AB designed the study and curated the data. SES and GE performed the formal analyses. SES prepared the figures and wrote the original draft and all authors contributed to review and editing. The project was supervised by KM, AR-D and AB. Funding was acquired by SES, GE, KM, AR-D and AB. All authors read and approved the final manuscript.

Funding
Open access funding provided by Karolinska Institute. This work was supported by Kj-Forsknar-ÅF [to S.E.S.], KI-Clinical Scientist Training Programme [to S.E.S.], Region Stockholm [clinical research appointment to G.E.], the Swedish Research Council [2017-01954 to GE], Svenska Läkaresällskapet [SLS-887241 to KM], Swedish Foundation for Strategic Research [SB12-00347 to A-R-D], Swedish Research Council [2016-00748 to A-R-D], Gething AB [4-1599/2018 to A-R-D], Region Stockholm [ALF project] [FOUI 995080 to A-B], the foundation Olle Engkvist Byggmästare [186 678 to A-B], Karolinska Institutet funding [FS-2020:0007 to A-B] and AIMES—Center for the Advancement of Integrated Medical and Engineering Sciences (www.aimesar.se) at Karolinska Institutet [1-249/2019] and KTH Royal Institute of Technology [VF-2019-0110]. The funding sources had no role in study design, data collection, analysis, interpretation, or writing of the report. The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The corresponding author also had final responsibility for the decision to submit for publication.

Availability of data and materials
Individual level data cannot be shared publicly because of patient confidentiality under current Swedish legislation. The data that support the findings of this study are available from Karolinska University Hospital but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Karolinska University Hospital and the appropriate ethics committee.

Declarations
Ethics approval and consent to participate
The study was performed in accordance with the Declaration of Helsinki and was approved by the regional ethics committee in Stockholm (Regionala etikprövningsnämnden i Stockholm, dnr 2017/1743-31/1 and 2018/52-32). The requirement for informed consent was waived by the same committee (Regionala etikprövningsnämnden i Stockholm).

Consent for publication
Not applicable.

Competing interests
There are no competing interest reported by any of the authors.

Author details
1AIMES—Center for the Advancement of Integrated Medical and Engineering Sciences at Karolinska Institutet and KTH Royal Institute of Technology, Stockholm, Sweden. 2Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden. 3Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, 171 77 Stockholm, Sweden. 4Department of Cardiology, Södersjukhuset, Stockholm, Sweden. 5Division of Clinical Microbiology, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Received: 2 February 2022   Accepted: 16 May 2022
Published online: 31 May 2022

References
1. Nakamura N, Uehara Y, Fukui S, Fujibayashi K, Yokokawa H, Naito T. Useful predictive factors for bacteremia among outpatients with pyelonephritis. Intern Med. 2018;57(10):1399–403.
